Enhertu Expands First-Line Breast Cancer Indication in India, Advancing the Treatment Landscape for HER2-Positive Metastatic Patients

For patients with metastatic breast cancer, first-line treatment often determines the starting point of the subsequent disease course. AstraZeneca Pharma India said India's Central Drugs Standard Control Organization has approved the import, sale, and distribution of Enhertu for an additional indication, allowing it to be used in combination with pertuzumab as a first-line treatment option for adults with unresectable or metastatic HER2-positive breast cancer.

The significance of this decision is not only that one drug has gained another regulatory label. HER2-positive breast cancer was once regarded as a more aggressive subtype, but as HER2-targeted antibodies, dual-antibody strategies, and antibody-drug conjugates have successively entered clinical practice, the pace of treatment has gradually been rewritten. Enhertu's approval in India effectively places this type of next-generation targeted delivery technology earlier in the treatment sequence.

Enhertu is jointly developed by AstraZeneca and Japan's Daiichi Sankyo. It is an antibody-drug conjugate designed to use an antibody that recognizes HER2 as a guide to deliver a cytotoxic drug to cancer cells expressing HER2. The appeal of this type of medicine lies in precise delivery, but clinical use still requires balancing efficacy, toxicity, patient condition, and existing treatment options.

According to information released by AstraZeneca Pharma India, the additional indication approved in India targets adults with unresectable or metastatic HER2-positive breast cancer, with use as a first-line treatment in combination with pertuzumab. Because the clinical data details provided in current public reports are limited, the full trial results, applicable patient conditions, and safety management underlying this regulatory decision still need to be based on the drug label and subsequent medical information.

India is an important global oncology treatment market, and its breast cancer burden is also considerable. For multinational pharmaceutical companies, obtaining approval for an additional indication helps expand commercial reach; for the healthcare system, the real impact will still depend on price, insurance or reimbursement arrangements, diagnostic accessibility, and whether HER2 testing can be implemented consistently across different regions.

This approval also reflects that competition in breast cancer treatment is moving from "whether there is a targeted drug" to "when to use it and how to sequence it." When antibody-drug conjugates are placed further forward in the treatment line, physicians face not only new options, but also more nuanced issues such as treatment sequencing, strategies after resistance, and long-term safety monitoring.

What can currently be confirmed is that India's regulator has given Enhertu a more formal position in first-line treatment for HER2-positive advanced breast cancer. As for the extent to which it can change patients' actual care, the answer will not only be written in approval documents, but will also be shaped by the speed of clinical adoption, affordability, and real-world treatment experience.